Curis (CRIS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, to be held virtually, with voting on five key proposals including director elections, executive compensation, auditor ratification, share authorization increase, and potential adjournment.
Record date for voting is March 23, 2026, with 39,978,693 shares outstanding and each share entitled to one vote.
Proxy materials are available online and by mail, and multiple voting methods are provided: internet, phone, mail, or during the virtual meeting.
Voting matters and shareholder proposals
Proposal 1: Election of two Class III directors for a three-year term.
Proposal 2: Advisory (non-binding) vote on executive compensation (say-on-pay).
Proposal 3: Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.
Proposal 4: Amendment to increase authorized shares of common stock from 283,757,150 to 567,514,300.
Proposal 5: Approval to adjourn the meeting if more time is needed to solicit votes for Proposal 4.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board is classified into three classes with staggered three-year terms; nominees for Class III are Martyn D. Greenacre and Kenneth I. Kaitin, Ph.D.
Majority of directors are independent per Nasdaq standards; all committee members are independent.
Board leadership is separated between CEO and Chairman roles.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and responsibilities.
Directors are expected to attend annual meetings and participate in ongoing education.
Latest events from Curis
- Emavusertib delivers deep, durable responses in blood cancers and advances toward registrational trials.CRIS
Corporate presentation1 Apr 2026 - Q4 2025 net income surged on Erivedge sale; PCNSL and CLL studies drive future growth.CRIS
Q4 202520 Mar 2026 - Shareholders to vote on share increase, PIPE-related issuances, and a new equity incentive plan.CRIS
Proxy Filing19 Feb 2026 - Registers 107.7M shares for resale by PIPE investors; no proceeds to company; clinical-stage biotech.CRIS
Registration Filing13 Feb 2026 - Shareholders to vote on major share increase, PIPE-related issuances, and a new incentive plan.CRIS
Proxy Filing9 Feb 2026 - Emavusertib gains EU ODD as Q2 net loss hits $11.8M; cash runway extends into Q1 2025.CRIS
Q2 20242 Feb 2026 - Emavusertib delivers strong early results in NHL and AML, with expansion into solid tumors underway.CRIS
H.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026 - Promising IRAK4 inhibitor data in AML and NHL drive pivotal trial plans and partnership interest.CRIS
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 net loss narrowed, emavusertib data positive, but cash only funds operations into mid-2025.CRIS
Q3 202414 Jan 2026